Immunocore Holdings Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
524
- Stock Symbol
-
IMCR
- Share Price
-
$26.38
- (As of Friday Closing)
Immunocore Holdings General Information
Description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Contact Information
Website
www.immunocore.comCorporate Office
- 92 Park Drive
- Milton Park, Oxon
- Abingdon OX14 4RY
- England, United Kingdom
Corporate Office
- 92 Park Drive
- Milton Park, Oxon
- Abingdon OX14 4RY
- England, United Kingdom
Immunocore Holdings Timeline
Immunocore Holdings Stock Performance
As of 20-Nov-2026, Immunocore Holdings’s stock price is $26.38. Its current market cap is $1.36B with 51.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $26.38 | $26.60 | $25.61 - $40.71 | $1.36B | 51.7M | 449K | -$0.64 |
Immunocore Holdings Financials Summary
As of 30-Sep-2026, Immunocore Holdings has a trailing 12-month revenue of $429M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,114,641 | 1,297,420 | 1,055,748 | 3,019,480 |
| Revenue | 429,304 | 400,016 | 310,202 | 249,428 |
| EBITDA | (15,537) | (20,144) | (55,507) | (69,632) |
| Net Income | (32,119) | (35,514) | (51,087) | (55,287) |
| Total Assets | 1,129,239 | 1,067,269 | 1,009,506 | 597,001 |
| Total Debt | 435,737 | 436,687 | 432,722 | 85,010 |
Immunocore Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunocore Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Immunocore Holdings Comparisons
Industry
Financing
Details
Immunocore Holdings Competitors (73)
One of Immunocore Holdings’s 73 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA |
Immunocore Holdings Patents
Immunocore Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202510176-D0 | Multispecific molecules | Pending | 25-Jun-2025 | ||
| GB-202418912-D0 | Specific binding molecules | Pending | 20-Dec-2024 | ||
| WO-2026132488-A1 | Specific binding molecules | Pending | 20-Dec-2024 | ||
| WO-2026110106-A1 | Intravenous solution stabilizer | Pending | 22-Nov-2024 | ||
| GB-202411647-D0 | Method | Inactive | 07-Aug-2024 | C07K16/2809 |
Immunocore Holdings Signals
Immunocore Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immunocore Holdings ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Immunocore Holdings Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Immunocore Ireland | Dublin, Ireland | 2018 |
Immunocore Holdings FAQs
-
When was Immunocore Holdings founded?
Immunocore Holdings was founded in 1999.
-
Where is Immunocore Holdings headquartered?
Immunocore Holdings is headquartered in Abingdon, United Kingdom.
-
What is the size of Immunocore Holdings?
Immunocore Holdings has 524 total employees.
-
What industry is Immunocore Holdings in?
Immunocore Holdings’s primary industry is Drug Discovery.
-
Is Immunocore Holdings a private or public company?
Immunocore Holdings is a Public company.
-
What is Immunocore Holdings’s stock symbol?
The ticker symbol for Immunocore Holdings is IMCR.
-
What is the current stock price of Immunocore Holdings?
As of 20-Nov-2026 the stock price of Immunocore Holdings is $26.38.
-
What is the current market cap of Immunocore Holdings?
The current market capitalization of Immunocore Holdings is $1.36B.
-
What is Immunocore Holdings’s current revenue?
The trailing twelve month revenue for Immunocore Holdings is $429M.
-
Who are Immunocore Holdings’s competitors?
Sarepta Therapeutics, Aldeyra Therapeutics, TME Pharma, Ayala Pharmaceuticals, and Sharp Therapeutics (Biotechnology) are some of the 73 competitors of Immunocore Holdings.
-
What is Immunocore Holdings’s annual earnings per share (EPS)?
Immunocore Holdings’s EPS for 12 months was -$0.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process